NO971403L - Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS - Google Patents

Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS

Info

Publication number
NO971403L
NO971403L NO971403A NO971403A NO971403L NO 971403 L NO971403 L NO 971403L NO 971403 A NO971403 A NO 971403A NO 971403 A NO971403 A NO 971403A NO 971403 L NO971403 L NO 971403L
Authority
NO
Norway
Prior art keywords
treatment
irds
ards
glucocorticoid
combination
Prior art date
Application number
NO971403A
Other languages
English (en)
Other versions
NO313405B1 (no
NO971403D0 (no
Inventor
Dietrich Haefner
Paul-Georg Germann
Klaus Eistetter
Ulrich Kilian
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of NO971403D0 publication Critical patent/NO971403D0/no
Publication of NO971403L publication Critical patent/NO971403L/no
Publication of NO313405B1 publication Critical patent/NO313405B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19971403A 1994-09-28 1997-03-25 Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS NO313405B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4434629A DE4434629C1 (de) 1994-09-28 1994-09-28 Zusammensetzungen zur Behandlung von IRDS und ARDS
PCT/EP1995/003816 WO1996009831A2 (de) 1994-09-28 1995-09-27 Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten

Publications (3)

Publication Number Publication Date
NO971403D0 NO971403D0 (no) 1997-03-25
NO971403L true NO971403L (no) 1997-04-17
NO313405B1 NO313405B1 (no) 2002-09-30

Family

ID=6529394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971403A NO313405B1 (no) 1994-09-28 1997-03-25 Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS

Country Status (26)

Country Link
US (1) US5891844A (no)
EP (1) EP0783314B1 (no)
JP (1) JP4425991B2 (no)
KR (1) KR100365030B1 (no)
CN (1) CN1100542C (no)
AT (1) ATE241372T1 (no)
AU (1) AU705099B2 (no)
BG (1) BG62556B1 (no)
CA (1) CA2201377C (no)
CZ (1) CZ292846B6 (no)
DE (2) DE4434629C1 (no)
DK (1) DK0783314T3 (no)
EE (1) EE03422B1 (no)
ES (1) ES2201120T3 (no)
FI (1) FI118886B (no)
HK (1) HK1003869A1 (no)
HU (1) HU226958B1 (no)
MX (1) MX9702303A (no)
NO (1) NO313405B1 (no)
NZ (1) NZ294587A (no)
PL (1) PL187496B1 (no)
PT (1) PT783314E (no)
RU (1) RU2157222C2 (no)
SK (1) SK284446B6 (no)
UA (1) UA43378C2 (no)
WO (1) WO1996009831A2 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
IL130658A (en) * 1997-02-17 2004-07-25 Altana Pharma Ag Preparations for the treatment of ARDS or IRDS containing 3 - (cyclopropylmethoxy) - N - (3, 5 - dichloro - 4 - pyridinyl) - 4 - (difluoromethoxy) benzamide and solvent for the lungs
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
CN1194833A (zh) * 1997-10-08 1998-10-07 刘柏宏 肺活素
US6858223B2 (en) 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
AU5400000A (en) * 1999-06-11 2001-01-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
US20030158087A1 (en) * 2000-04-12 2003-08-21 Dietrich Hafner Novel use of fulmonary surfactant for the prophylaxis or early treatment if acute fulmonary diseases
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
EP1280520B2 (en) * 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
AU2002357168A1 (en) * 2001-12-12 2003-07-09 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
JP2006527737A (ja) 2003-06-16 2006-12-07 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントとｐｄｅ５阻害剤とを含有する肺疾病の治療用の組成物
DK1670482T4 (da) * 2003-09-16 2022-08-22 Covis Pharma B V Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
PL1841458T3 (pl) 2005-01-06 2012-05-31 Discovery Lab Inc Schemat stosowania środka powierzchniowo czynnego do leczenia lub zapobiegania dysplazji oskrzelowo-płucnej
KR100891595B1 (ko) 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
KR20090060348A (ko) * 2006-09-19 2009-06-11 디스커버리 래보래토리스, 인크. 폐 계면활성제 제제 및 점액 클리어런스 촉진 방법
EP2022798A1 (en) * 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
WO2012077127A1 (en) * 2010-12-10 2012-06-14 Indian Institute Of Technology, Bombay A protein free surfactant composition for pulmonary diseases and a process for preparing the same
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN106310280A (zh) * 2016-08-18 2017-01-11 滨州医学院 地瑞那韦增强糖皮质激素抗炎作用的医药新用途
RU2757902C2 (ru) * 2016-12-22 2021-10-22 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Терапевтическая комбинация для лечения развивающейся bpd, содержащая легочный сурфактант и стероид

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
NZ294587A (en) 1998-07-28
PL319608A1 (en) 1997-08-18
UA43378C2 (uk) 2001-12-17
ATE241372T1 (de) 2003-06-15
CN1100542C (zh) 2003-02-05
WO1996009831A2 (de) 1996-04-04
US5891844A (en) 1999-04-06
AU705099B2 (en) 1999-05-13
JPH10506119A (ja) 1998-06-16
CN1163571A (zh) 1997-10-29
BG62556B1 (bg) 2000-02-29
MX9702303A (es) 1997-06-28
EE03422B1 (et) 2001-06-15
NO313405B1 (no) 2002-09-30
FI118886B (fi) 2008-04-30
FI971277A0 (fi) 1997-03-26
CZ94097A3 (en) 1997-09-17
ES2201120T3 (es) 2004-03-16
PL187496B1 (pl) 2004-07-30
KR970706006A (ko) 1997-11-03
EE9700084A (et) 1997-10-15
DK0783314T3 (da) 2003-12-01
SK40197A3 (en) 1998-02-04
EP0783314A2 (de) 1997-07-16
JP4425991B2 (ja) 2010-03-03
NO971403D0 (no) 1997-03-25
CA2201377A1 (en) 1996-04-04
BG101441A (en) 1997-09-30
EP0783314B1 (de) 2003-05-28
SK284446B6 (sk) 2005-04-01
CZ292846B6 (cs) 2003-12-17
HUT77931A (hu) 1998-11-30
HK1003869A1 (en) 1998-11-13
KR100365030B1 (ko) 2003-03-10
DE4434629C1 (de) 1996-06-27
WO1996009831A3 (de) 1996-05-23
CA2201377C (en) 2008-07-29
PT783314E (pt) 2003-10-31
FI971277A (fi) 1997-05-27
HU226958B1 (en) 2010-03-29
RU2157222C2 (ru) 2000-10-10
AU3742895A (en) 1996-04-19
DE59510705D1 (de) 2003-07-03

Similar Documents

Publication Publication Date Title
NO971403L (no) Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS
FI910393A (fi) Semi-termoplastisk matriskomposition med vaermestabilt formbestaendigt minne.
DE3586959T2 (de) Desinfektionsverfahren sowie zusammensetzung dafuer.
NO995111D0 (no) Konditorblandinger
FI893127A0 (fi) Komposition som bildar en vattenavstoetande film.
DE3673066D1 (de) Fluorelastomerzusammensetzung und diese enthaltende waermeschrumpfbare gegenstaende.
NO871091D0 (no) Komposittanordning for katodisk beskyttelse av substrater i kontakt med denne, og anvendelse av anordningen.
DK40986D0 (da) 4h-1-benzopyran-4-oner og deres svovlholdige analoge, og farmaceutiske kompositioner indeholdende forbindelserne
DE3264461D1 (en) 1-dodecylazacycloheptan-2-one used in anti-inflammatory compositions
DE3575288D1 (de) Feuerfeste zusammensetzung und daraus hergestellte koerper.
HK1006840A1 (en) Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
MY107976A (en) Improvements in or relating to organic compounds
DK399985D0 (da) 6-substituerede mitomycin-analoge, deres anvendelse inden for medicinen og kompositioner indeholdende forbindelserne
NO156851B (no) Innretning for videretransport av reker i innrettet og ordnet tilstand.
FR2543415B1 (fr) Perfectionnements apportes aux pietements pivotants, et mobilier, notamment elements de barriere deplacable, equipe de tels pietements
DE3486407T2 (de) Zusammensetzung zur Kontrolle der Hämophilie bei Säugetieren.
DE69322629T2 (de) Selbstkonvergierende und in der geometrie korrigierte elektronenablenkeinheit für kathodenstrahlröhren
DK330687A (da) Forbindelser og farmaceutiske kompositioner, der er anvendelige som cardiotoniske midler
FR2543416B1 (fr) Perfectionnements apportes aux pietements pivotants, et mobilier, notamment elements de barriere deplacable, equipe de tels pietements
DE69112642T2 (de) Glutaminhaltige lyophilisierte aminokarbonsäurenzusammensetzungen.
MY117887A (en) Phenyl-substituted 1, 4 - dihydropyridines
DK199983D0 (da) Analoge til neurohypofysiske hormoner med haemmende egenskaber
DK346387A (da) Fremgangsmaade til at reducere alkaliindholdet i cementklinker
Oliveira et al. Liquidus and Peritectic Reactions in the Variable Valency System Ce (Co sub 1--x Ni sub x) sub 2(0<= x<= 1. 0)
Yasuda Study of the [Lambda] polarization in proton-nucleus interactions at 12 GEV

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

MM1K Lapsed by not paying the annual fees